Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092707 | 0.82 | DRD2 (0.42) | GNAO1GNAI3GNAI1 | |
| SCHEMBL10052292 | 0.82 | ARG1 (0.37) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL25075208 | 0.80 | NCF1 (0.39) | NCF1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL19147260 | 0.80 | TP53 (0.37) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL8252286 | 0.80 | CYP1A2 (0.40) | CARM1PRMT6PRMT1PRMT8ACHE | |
| SCHEMBL101938 | 0.80 | SLC18A3 (0.41) | CARM1PRMT6PRMT1PRMT8GNAO1 | |
| SCHEMBL12309037 | 0.79 | NCF1 (0.37) | NCF1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25108944 | 0.78 | SIGMAR1 (0.42) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL25075441 | 0.78 | PRMT6 (0.33) | CARM1PRMT6PRMT1PRMT8GNAO1 | |
| SCHEMBL10092695 | 0.78 | GNAO1 (0.46) | HTR4GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | NCF1 1371/4885CARM1 3680/4885PRMT6 1790/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | NCF1 1466/4885CARM1 2944/4885PRMT6 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.